

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. and Teva Canada Limited that the shortages of pms-Salbutamol Polyneb 22 mg/ml Inhalation Unit Dose Solution (DIN 02208237) and Teva-Salbutamol Sterinebs P.F. 2 mg/ml Inhalation Unit Dose Solution (DIN 02173360) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 15, 2016**.

SALBUTAMOL SULFATE

2 MG / ML (BASE) INHALATION UNIT DOSE SOLUTION

00002208237	PMS-SALBUTAMOL POLYNEB	PMS	\$ 0.2748
00002173360	TEVA-SALBUTAMOL STERINEBS P.F.	TEV	\$ 0.2748
00002239366	RATIO-SALBUTAMOL UNI DOSE P.F.	RPH	\$ 0.2885
00002213427	VENTOLIN NEBULES P.F.	GSK	\$ 0.7970

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Quinapril 40 mg Tablet (DIN 02248502) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

QUINAPRIL

40 MG (BASE) ORAL TABLET

00002248502	APO-QUINAPRIL	APX	\$ 0.6867
00001947699	ACCUPRIL	PFI	\$ 0.9238

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Prazo 1 mg Tablet (DIN 00882801) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

PRAZOSIN HCL

1 MG (BASE) ORAL TABLET

00000882801	APO-PRAZO	APX	\$ 0.2743
00001934198	TEVA-PRAZOSIN	TEV	\$ 0.2766

... continued from previous page

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Prazo 2 mg Tablet (DIN 00882828) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

PRAZOSIN HCL

2 MG (BASE) ORAL TABLET

00000882828	APO-PRAZO	APX	\$ 0.3725
00001934201	TEVA-PRAZOSIN	TEV	\$ 0.3825

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Prazo 5 mg Tablet (DIN 00882836) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

PRAZOSIN HCL

5 MG (BASE) ORAL TABLET

00000882836	APO-PRAZO	APX	\$ 0.5121
00001934228	TEVA-PRAZOSIN	TEV	\$ 0.5259

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Rythmol 300 mg Tablet (DIN 00603716) manufactured by BGP Pharma ULC, and Apo-Propafenone 300 mg Tablet (DIN 02243325) manufactured by Apotex Inc., pms-Propafenone 300 mg Tablet (DIN 02294575) manufactured by Pharmascience Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

BGP Pharma ULC has advised Alberta Blue Cross that the shortage Rhythmol 300 mg Tablet (DIN 00603716) has now been resolved. As a result, pms-Propafenone 300 mg Tablet (DIN 02294575) will no longer be considered as a temporary benefit for the *ADBL* **after January 15, 2016**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)
FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)
